EBS Stock Forecast 2025-2026
Distance to EBS Price Targets
EBS Price Momentum
10 Quality Stocks Worth Considering Now
Researching Emergent BioSolutions (EBS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on EBS and similar high-potential opportunities.
Latest EBS Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, EBS has a bullish consensus with a median price target of $13.50 (ranging from $12.00 to $15.00). The overall analyst rating is Buy (7.3/10). Currently trading at $5.17, the median forecast implies a 161.1% upside. This outlook is supported by 2 Buy, 0 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 190.1% upside. Conversely, the most conservative target is provided by Robert Wasserman at Benchmark, suggesting a 132.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EBS Analyst Ratings
EBS Price Target Range
Latest EBS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EBS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 21, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $15.00 |
| Mar 4, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $15.00 |
| Jan 21, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $15.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $15.00 |
| Dec 30, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Initiates | $15.00 |
| Nov 7, 2024 | Benchmark | Robert Wasserman | Buy | Maintains | $12.00 |
| Sep 13, 2024 | Rodman & Renshaw | Brandon Folkes | Buy | Reiterates | $16.00 |
| Aug 22, 2024 | Rodman & Renshaw | Buy | Initiates | $16.00 | |
| Aug 16, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $8.00 |
| Aug 9, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $8.00 |
| Jul 3, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $8.00 |
| Jul 2, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $8.00 |
| Jun 24, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $8.00 |
| Jun 21, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $8.00 |
| Jun 20, 2024 | Benchmark | Robert Wasserman | Buy | Maintains | $8.00 |
| Apr 11, 2024 | Benchmark | Robert Wasserman | Buy | Reiterates | $5.00 |
| Mar 7, 2024 | Benchmark | Robert Wasserman | Buy | Upgrade | $5.00 |
| Nov 20, 2023 | JP Morgan | Jessica Fye | Underweight | Reinstates | $0.00 |
| Aug 29, 2023 | Benchmark | Robert Wasserman | Hold | Downgrade | $0.00 |
| May 31, 2023 | Benchmark | Robert Wasserman | Buy | Reiterates | $22.00 |
Emergent BioSolutions Inc. (EBS) Competitors
The following stocks are similar to Emergent BioSolutions based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Emergent BioSolutions Inc. (EBS) Financial Data
Emergent BioSolutions Inc. has a market capitalization of $280.92M with a P/E ratio of -1.4x. The company generates $1.04B in trailing twelve-month revenue with a -18.3% profit margin.
Revenue growth is -29.6% quarter-over-quarter, while maintaining an operating margin of -2.2% and return on equity of -33.7%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Emergent BioSolutions Inc. (EBS) Business Model
About Emergent BioSolutions Inc.
Develops and manufactures medical products for health threats.
Emergent BioSolutions generates revenue by developing, manufacturing, and distributing a diverse range of medical products that combat public health threats, including vaccines and therapeutics. The company collaborates with government and commercial partners to supply biodefense solutions and medical devices, which form a significant portion of its income.
Headquartered in Gaithersburg, Maryland, Emergent BioSolutions is integral to national security programs with its production of anthrax and smallpox vaccines. The company emphasizes emergency preparedness and health security, positioning itself as a vital contributor to global health initiatives and the pharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
900
CEO
Mr. Joseph C. Papa Jr.
Country
United States
IPO Year
2006
Website
www.emergentbiosolutions.comEmergent BioSolutions Inc. (EBS) Latest News & Analysis
Emergent BioSolutions is set to spearhead the commercial launch of intranasal naloxone in Canada to enhance access and address opioid overdose issues.
Emergent BioSolutions' initiative to launch intranasal naloxone in Canada could boost revenue, enhance market position, and address a critical public health issue, influencing investor sentiment positively.
Emergent BioSolutions Inc. announced the granting of an equity award to a new employee under its 2023 Inducement Plan, as part of its efforts to attract talent.
Emergent BioSolutions' equity award indicates growth and investment in talent, potentially enhancing innovation and operational efficiency, which can positively impact stock performance.
Emergent BioSolutions Inc. has sold its Baltimore-Bayview manufacturing facility to Syngene International for approximately $36.5 million, pending customary post-closing adjustments.
Emergent BioSolutions' $36.5 million sale of its manufacturing facility may enhance liquidity and focus on core operations, potentially impacting future growth and investor sentiment.
Emergent BioSolutions (NYSE: EBS) has secured approximately $27 million in international orders for its medical countermeasures, with delivery planned for 2025.
Emergent BioSolutions' $27 million international orders for medical countermeasures indicate strong demand, potentially boosting revenue and market confidence in the company's growth prospects.
Emergent BioSolutions (NYSE: EBS) has invested in Swiss Rockets Ltd to support research and development of innovative biotech solutions, enhancing its commitment to public health advancements.
Emergent BioSolutions' investment in Rocketvax enhances its portfolio and growth potential in biotech, signaling confidence in innovative vaccine development, which can drive future revenue and market competitiveness.
Emergent BioSolutions Inc. (NYSE: EBS) is enhancing partnerships to improve opioid emergency preparedness, focusing on expanding access to NARCAN® Nasal Spray as overdose death rates decline.
Emergent BioSolutions' commitment to opioid preparedness and partnerships may enhance its market position and revenue potential, particularly as overdose rates decline, signaling effective interventions.
Frequently Asked Questions About EBS Stock
What is Emergent BioSolutions Inc.'s (EBS) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, Emergent BioSolutions Inc. (EBS) has a median price target of $13.50. The highest price target is $15.00 and the lowest is $12.00.
Is EBS stock a good investment in 2025?
According to current analyst ratings, EBS has 2 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $5.17. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EBS stock?
Wall Street analysts predict EBS stock could reach $13.50 in the next 12 months. This represents a 161.1% increase from the current price of $5.17. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Emergent BioSolutions Inc.'s business model?
Emergent BioSolutions generates revenue by developing, manufacturing, and distributing a diverse range of medical products that combat public health threats, including vaccines and therapeutics. The company collaborates with government and commercial partners to supply biodefense solutions and medical devices, which form a significant portion of its income.
What is the highest forecasted price for EBS Emergent BioSolutions Inc.?
The highest price target for EBS is $15.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 190.1% increase from the current price of $5.17.
What is the lowest forecasted price for EBS Emergent BioSolutions Inc.?
The lowest price target for EBS is $12.00 from Robert Wasserman at Benchmark, which represents a 132.1% increase from the current price of $5.17.
What is the overall EBS consensus from analysts for Emergent BioSolutions Inc.?
The overall analyst consensus for EBS is bullish. Out of 11 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $13.50.
How accurate are EBS stock price projections?
Stock price projections, including those for Emergent BioSolutions Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
